SLRX - Salarius Pharmaceuticals, Inc. Stock Price and Quote

SLRX [NASD]

Index	-	P/E	-	EPS (ttm)	-14.18	Insider Own	0.90%	Shs Outstand	2.25M	Perf Week	3.63%
Market Cap	4.64M	Forward P/E	-	EPS next Y	-4.89	Insider Trans	0.00%	Shs Float	2.17M	Perf Month	-7.41%
Income	-29.30M	PEG	-	EPS next Q	-2.15	Inst Own	16.30%	Short Float / Ratio	5.80% / 0.71	Perf Quarter	66.67%
Sales	0.00M	P/S	-	EPS this Y	37.90%	Inst Trans	-6.68%	Short Interest	0.13M	Perf Half Y	-57.78%
Book/sh	7.39	P/B	0.28	EPS next Y	34.30%	ROA	-90.50%	Target Price	70.50	Perf Year	-80.49%
Cash/sh	7.53	P/C	0.28	EPS next 5Y	-	ROE	-98.10%	52W Range	1.07 - 11.10	Perf YTD	30.72%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-33.10%	52W High	-81.98%	Beta	0.97
Dividend %	-	Quick Ratio	5.80	Sales past 5Y	12.70%	Gross Margin	-	52W Low	86.92%	ATR	0.16
Employees	16	Current Ratio	5.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	43.55	Volatility	8.85% 6.39%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-207.40%	Profit Margin	-	Rel Volume	0.06	Prev Close	2.08
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	178.09K	Price	2.00
Recom	1.00	SMA20	-4.13%	SMA50	-12.50%	SMA200	-42.70%	Volume	6,173	Change	-3.85%

Apr-27-20

Initiated

Ladenburg Thalmann

Buy

$3.80

Mar-27-23 08:30AM	Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update GlobeNewswire
Mar-15-23 11:00AM	Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting GlobeNewswire
Mar-07-23 08:00AM	Salarius Pharmaceuticals to Present In Vitro Data on Seclidemstat in Small Cell Lung Cancer at the Keystone Symposia GlobeNewswire
Feb-16-23 08:30AM	Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas GlobeNewswire
Jan-27-23 08:30AM	Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit GlobeNewswire -5.47%
08:30AM	Loading…
Jan-19-23 08:30AM	Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit GlobeNewswire +52.99%
Jan-05-23 08:00AM	Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein Degraders GlobeNewswire
Dec-13-22 08:01AM	Investigators Present Clinical Data on Salarius Pharmaceuticals Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting GlobeNewswire -5.32%
08:00AM	Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting GlobeNewswire
Dec-08-22 08:00AM	Salarius Pharmaceuticals to Hold Conference Call to Discuss Recent Clinical and Preclinical Data on Lead Programs, Including Presentations at ASH GlobeNewswire
Dec-01-22 08:00AM	Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas GlobeNewswire -5.18%
Nov-10-22 08:30AM	Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update GlobeNewswire
Nov-03-22 09:57AM	Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting GlobeNewswire
Oct-27-22 08:30AM	Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference GlobeNewswire -14.40%
Oct-19-22 08:30AM	Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference GlobeNewswire -15.73%
08:30AM	Loading…
Oct-18-22 08:30AM	Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas GlobeNewswire -45.18%
Oct-14-22 08:43AM	Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split GlobeNewswire -13.81%
Sep-20-22 12:00PM	Salarius Pharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference GlobeNewswire
Sep-13-22 08:00AM	Salarius Pharmaceuticals CEO Issues Letter to Stockholders GlobeNewswire +10.10%
Aug-22-22 08:30AM	Salarius Pharmaceuticals Adds Two Mayo Clinic Sites to its Ongoing Phase 1/2 Trial of Seclidemstat as a Treatment for Ewings Sarcoma and FET-Rearranged Sarcomas GlobeNewswire -9.29%
Aug-08-22 08:30AM	Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update GlobeNewswire +9.95%
Aug-04-22 08:30AM	Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas GlobeNewswire
Aug-02-22 08:30AM	Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement GlobeNewswire -6.07%
Jul-29-22 09:15AM	Salarius Pharmaceuticals to Host Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 8, 2022 GlobeNewswire
Jun-09-22 07:33AM	Salarius Pharmaceuticals to Participate in BIO International Convention 2022 GlobeNewswire
May-18-22 04:10PM	Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference GlobeNewswire +20.62%
May-12-22 04:05PM	Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results GlobeNewswire +38.75%
May-11-22 04:05PM	Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration GlobeNewswire -16.93%
May-05-22 07:30AM	Salarius Pharmaceuticals to Report First Quarter 2022 Financial Results and Highlight Recent Company Progress GlobeNewswire
Apr-22-22 08:30AM	Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering GlobeNewswire -20.54%
04:05PM	Loading…
Mar-10-22 04:05PM	Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2021 Financial Results GlobeNewswire +33.40%
Mar-03-22 07:31AM	Salarius Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results and Highlight Recent Company Progress GlobeNewswire
Feb-17-22 08:01AM	Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference GlobeNewswire
Feb-15-22 09:00AM	Diamond Equity Research to Host Emerging Growth Invitational Virtual Investor Conference on February 24, 2022 GlobeNewswire
Feb-08-22 08:00AM	Salarius Pharmaceuticals to Participate in the 2022 BIO CEO & Investor Conference GlobeNewswire
Feb-03-22 07:30AM	Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program GlobeNewswire
Jan-14-22 01:52PM	Salarius expands oncology drug pipeline with DeuteRx portfolio acquisition American City Business Journals
Jan-13-22 07:00AM	Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC GlobeNewswire
Jan-06-22 12:45PM	Salarius Pharmaceuticals to Present at Virtual H.C. Wainwright BioConnect, Participate in Virtual Biotech Showcase and BIO Partnering @ JPM During "J.P. Morgan Week 2022" GlobeNewswire -6.06%
Dec-29-21 08:03AM	Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial GlobeNewswire -6.19%
Dec-20-21 08:35AM	Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing CNW Group
Dec-15-21 08:31AM	Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum GlobeNewswire
Dec-14-21 08:35AM	Virtual Conference for Life Sciences Companies Broadcast Live December 16th CNW Group
Nov-29-21 08:01AM	Salarius Pharmaceuticals to Participate in Annual Benchmark Company Discovery One-on-One Conference GlobeNewswire
Nov-04-21 04:05PM	Salarius Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress GlobeNewswire
Oct-28-21 03:06PM	Will Salarius (SLRX) Report Negative Earnings Next Week? What You Should Know Zacks
Oct-26-21 08:01AM	Salarius Pharmaceuticals to Report Third Quarter 2021 Financial Results and Highlight Recent Company Progress GlobeNewswire
Oct-07-21 09:05AM	Salarius Pharmaceuticals and Nationwide Childrens Hospital Disclose Research Findings from Presentation at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics GlobeNewswire
Oct-05-21 08:01AM	Salarius Pharmaceuticals to Present at the 2021 BioFuture Conference GlobeNewswire
Sep-30-21 04:35PM	Salarius Pharmaceuticals and Nationwide Childrens Hospital Announce Poster Presentation at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics GlobeNewswire
Sep-28-21 07:01AM	Salarius Pharmaceuticals Receives $2.7 Million in Payment from the Cancer Prevention and Research Institute of Texas GlobeNewswire
Sep-27-21 08:03AM	Salarius Pharmaceuticals to Present at the Virtual Benzinga Healthcare Small Cap Conference GlobeNewswire -5.22%
Sep-22-21 07:33AM	Salarius Pharmaceuticals and Fox Chase Cancer Center Launch Research Partnership GlobeNewswire
Sep-20-21 08:35AM	Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing GlobeNewswire
07:33AM	Salarius Pharmaceuticals Added to FTSE Global Micro Cap Index GlobeNewswire
Sep-15-21 08:03AM	Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum GlobeNewswire
Sep-10-21 08:35AM	Life Sciences Virtual Investor Conference: Company Executives Present Live September 16th GlobeNewswire
Sep-08-21 08:13AM	Salarius Pharmaceuticals to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire
Aug-12-21 02:00PM	Salarius Pharmaceuticals to Present at the Virtual Diamond Equity Research Emerging Growth Invitational GlobeNewswire
09:00AM	Diamond Equity Research Emerging Growth Invitational Summer 2021 Spotlight Virtual Conference GlobeNewswire
Aug-10-21 06:16AM	Here's Why We're Not Too Worried About Salarius Pharmaceuticals' (NASDAQ:SLRX) Cash Burn Situation Simply Wall St.
Aug-05-21 07:32AM	Salarius Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress GlobeNewswire
Jul-29-21 07:33AM	Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results GlobeNewswire
Jul-14-21 08:05AM	Salarius Pharmaceuticals Announces Aundrietta Duncan, Ph.D., To Present During Virtual Epigenetic Therapeutic Targets Summit GlobeNewswire
Jul-13-21 07:33AM	Salarius Pharmaceuticals Adds Fox Chase Cancer Center to Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas GlobeNewswire
Jul-09-21 07:33AM	Salarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference GlobeNewswire +7.92%
Jun-17-21 08:03AM	REMINDER: Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event GlobeNewswire
Jun-15-21 07:30AM	Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers GlobeNewswire
Jun-10-21 01:30PM	Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event GlobeNewswire
Jun-07-21 07:35AM	Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstats Safety, Dosing, and Drug Activity at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting GlobeNewswire
May-19-21 05:01PM	Salarius Pharmaceuticals Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting GlobeNewswire -6.21%
May-12-21 04:05PM	Salarius Pharmaceuticals Reports First Quarter Financial Results with Business Highlights GlobeNewswire
02:45PM	Salarius Pharmaceuticals Inc to Host Earnings Call ACCESSWIRE
May-05-21 07:05AM	Salarius Pharmaceuticals to Report First Quarter 2021 Financial Results GlobeNewswire
Apr-29-21 07:30AM	Salarius Pharmaceuticals Announces Titles of Three Abstracts Accepted for Poster Presentations at American Society of Clinical Oncology 2021 Annual Meeting GlobeNewswire
Apr-19-21 07:30AM	Salarius Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentations at the 2021 American Society of Clinical Oncology Annual Meeting GlobeNewswire
Mar-18-21 04:05PM	Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2020 Financial Results GlobeNewswire -5.06%
02:30PM	Salarius Pharmaceuticals Inc to Host Earnings Call ACCESSWIRE
Mar-11-21 04:15PM	Salarius Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results GlobeNewswire +5.37%
Mar-08-21 04:05PM	Salarius Announces Closing of $23 Million Underwritten Public Offering of Common Stock Following Full Exercise of Over-Allotment Option GlobeNewswire +5.47%
Mar-04-21 08:30AM	Salarius Announces Pricing of $20 Million Underwritten Public Offering of Common Stock GlobeNewswire -16.15%
Mar-03-21 04:05PM	Salarius Announces Proposed Public Offering of Common Stock GlobeNewswire -13.90%
Feb-24-21 07:00AM	Salarius Pharmaceuticals Initiates Expansion Stage of Phase 1/2 Clinical Trial of Seclidemstat in Patients with Ewing Sarcoma and Ewing-Related Sarcomas GlobeNewswire +10.36%
Feb-22-21 07:30AM	Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Virtual Conference GlobeNewswire -9.62%
Feb-17-21 09:00AM	Diamond Equity Research Emerging Growth Invitational Winter 2021 Virtual Conference ACCESSWIRE
07:30AM	Salarius Completes Dose-Escalation Stage of Phase 1/2 Clinical Trial in Relapsed and Refractory Ewing Sarcoma Patients, Initiates Expansion Stage in Ewing and Ewing-Related Sarcoma Patients GlobeNewswire
Feb-16-21 07:30AM	Salarius Pharmaceuticals to Present at BIO CEO & Investor Digital Conference GlobeNewswire
Feb-10-21 06:21AM	Did Business Growth Power Salarius Pharmaceuticals' (NASDAQ:SLRX) Share Price Gain of 236%? Simply Wall St. +6.76%
Jan-21-21 08:05AM	Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement GlobeNewswire -6.67%
Jan-15-21 07:30AM	Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17 Investor Conference GlobeNewswire
Jan-13-21 07:30AM	Salarius Pharmaceuticals Receives Second Installment of $1.7 Million in Payments from the Cancer Prevention and Research Institute of Texas GlobeNewswire
Dec-22-20 07:30AM	Salarius Pharmaceuticals to Participate in Biotech Showcase Digital and BIO @ JPM During "J.P. Morgan Week 2021" GlobeNewswire
Dec-11-20 11:32AM	Salarius Announces Exercise Of Warrants For $3.5 Million Of Gross Proceeds To Be Used For Ongoing Development Of Seclidemstat GlobeNewswire -31.34%
Dec-10-20 09:28AM	Salarius Pharmaceuticals Receives First Installment of $1.7 Million in Payments from the Cancer Prevention and Research Institute of Texas GlobeNewswire +24.07%
Nov-17-20 07:30AM	Salarius Pharmaceuticals to Participate in A.G.P.s Virtual Healthcare Symposium GlobeNewswire
Nov-11-20 04:05PM	Salarius Pharmaceuticals Reports Business Highlights and Third Quarter 2020 Financial Results GlobeNewswire
02:30PM	Salarius Pharmaceuticals Inc to Host Earnings Call ACCESSWIRE
Nov-04-20 07:30AM	Salarius Pharmaceuticals to Report Third Quarter 2020 Financial Results GlobeNewswire
Oct-13-20 07:30AM	Salarius Pharmaceuticals to Present at BIO Investor Forum Digital GlobeNewswire
Sep-21-20 08:35AM	Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing GlobeNewswire

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lieber Jonathan I	Director	Jun 07	Buy	0.19	37,500	7,016	37,500	Jun 08 03:12 PM
Burleson Tess	Director	Jun 07	Buy	0.18	27,700	4,986	32,050	Jun 08 03:14 PM
McVicar William K.	Director	Jun 06	Buy	0.19	26,553	5,000	26,553	Jun 07 04:33 PM
HANISH ARNOLD C	Director	Jun 03	Buy	0.18	28,000	5,152	46,350	Jun 06 08:33 PM
Rosenblum Mark J	Exec VP Finance, CFO	May 31	Buy	0.18	28,000	5,040	148,319	May 31 05:13 PM
Arthur David J.	Chief Executive Officer	May 26	Buy	0.18	22,000	3,997	281,674	May 31 05:17 PM
Arthur David J.	Chief Executive Officer	May 26	Buy	0.18	21,900	3,987	303,574	May 31 05:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience